Who are Immatics N.V.'s main suppliers?

Immatics N.V. (IMTX) key suppliers include: CytoMed Therapeutics Limited, Moderna, Inc., Thermo Fisher Scientific Inc., Thermo Fisher Scientific Inc.. View the full supplier network at chainsifter.com/chain/IMTX.

Who are Immatics N.V.'s major customers?

Immatics N.V. (IMTX) key customers include: PATHEON-UK-LIMITED, Thermo Fisher Scientific Inc., Thermo Fisher Scientific Inc., Editas Medicine, Inc., Editas Medicine, Inc. and 6 more. View the full customer network at chainsifter.com/chain/IMTX.

What sector is Immatics N.V. in?

Immatics N.V. (IMTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Immatics N.V. Suppliers, Customers & Supply Chain (IMTX)

4Suppliers

11Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Immatics N.V. (IMTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

2Distinct source URLs

5High confidence

0.752Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Immatics N.V. Suppliers

Ticker	Name	Confidence	Evidence
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n…
MRNA	Moderna, Inc.	72%	Reciprocal relationship from MRNA graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from MRNA graph: er the greatest possible impact to people through mRNA medicines. COMMERCIAL…
TMO	Thermo Fisher Scientific Inc.	72%	A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement contains customary termination and cancel…
TMO	Thermo Fisher Scientific Inc.	72%	Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and …

Immatics N.V. Customers

Ticker	Name	Confidence	Evidence
PATHEON-UK-LIMITED	PATHEON-UK-LIMITED	85%	A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement contains customary termination and cancel…
TMO	Thermo Fisher Scientific Inc.	85%	A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement contains customary termination and cancel…
TMO	Thermo Fisher Scientific Inc.	85%	Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon…
EDIT	Editas Medicine, Inc.	72%	Reciprocal relationship from EDIT graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from EDIT g…
EDIT	Editas Medicine, Inc.	72%	expired Service Options outstanding on December 31, Service Options exercisable on December 31, Weighted average remaining contract life (years) Service Options outstanding as of December 31, 2022: F…
GDTC	CytoMed Therapeutics Limited	72%	Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit…
GNMSF	Genmab A/S	72%	Reciprocal relationship from GNMSF graph: Reciprocal relationship from IMTX graph: future taxable profits together with future tax planning strategies. Due to the Group’s history of loss-making over …
GNMSF	Genmab A/S	72%	future taxable profits together with future tax planning strategies. Due to the Group’s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group h…
MRNA	Moderna, Inc.	72%	Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and complia…
ADVANCED-TCER-ACTIVITIES-THE-GROUP	ADVANCED-TCER-ACTIVITIES-THE-GROUP	62%	ontain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and Moderna. They clearly state deliv…
IMMATICS-GMBH	IMMATICS-GMBH	62%	tanding on December 31, 2024 10.09 3,680,000 PSUs exercisable on December 31, 2024 — — Weighted average remaining contract life (years) 5.60 PSUs outstanding as of December 31, 2023: 2023 Weighted av…

Immatics N.V. Debt Obligations

Instrument	Description	Confidence	Evidence
IMTX-DEBT	Debt stack $17.6M	90%	Market cache reports total debt of $17.6M.

Immatics N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immatics N.V..

Immatics N.V. Ownership

Holder	Name	Confidence	Evidence
IMTX-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME	T. Rowe Price Investment Management, Inc.	90%	13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 83 tracked holders.

Immatics N.V. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ICLR	ICON Public Limited Company	100.00	2
GH	Guardant Health, Inc.	100.00	2
GHRS	GH Research PLC	100.00	2
GILD	Gilead Sciences, Inc.	100.00	2
GNMSF	Genmab A/S	100.00	1	['customer']
IDXG	Interpace Biosciences, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	1	['customer', 'supplier']
BTAI	BioXcel Therapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
GMAB	Genmab A/S	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	1	['customer']
BHPLF	BHP Group Limited	100.00	2
BOLT	Bolt Biotherapeutics, Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	2
IPSC	Century Therapeutics, Inc.	100.00	2

Immatics N.V. Supply Chain